Inflammatory Response Research

Inflammatory Response Research is a private U.S. drug development company focused on inflammatory and acute care conditions. The company is developing IRR-401, a proprietary oral combination of levocetirizine and montelukast, which has been studied in COVID-19 and has also been described by the company as applicable to influenza and other inflammation-mediated conditions. IRR has also described a parallel injectable program, referred to as a First Response injectable, aimed at acute inflammation associated with traumatic brain injury, polytrauma, and severe influenza. Available public materials indicate the company was founded in 2011 and is headquartered in Santa Barbara, California. Public information on its pipeline remains limited, and much of the disclosed development narrative comes from company-linked profiles and a 2022 press release.